Adiso療法

2023年2月9日

新聞由分享本文提供分享本文康科德，馬薩諸塞州。2023年2月9日/美通社/——Adiso Therapeutics, Inc.，一家臨床階段生物技術公司，致力於創造治療炎症性疾病的藥物，改善患者及其家人的生活，已任命Srikar Guntaka，醫學博士為其醫療總監。在新設立的職位上，Guntaka博士將利用他10年的醫療事務和臨床開發經驗，幫助Adiso推進其用於治療炎症性疾病的新型差異化療法。最近，他擔任Mirum Pharmaceuticals的醫療總監、臨床開發主管，領導成人volixibat多種適應症的全球開發的各個方麵。Adiso首席執行官Scott Megaffin表示:“我們很高興在公司和我們的管道的關鍵時期歡迎Srikar。“他在免疫學和胃腸道疾病方麵的治療專業知識，以及他執行後期試驗的能力，與我們的目標一致，即推進ADS051治療潰瘍性結腸炎，並在ADS032(一種NLRP3/NLRP1雙炎症小體抑製劑)出色的臨床前工作的基礎上進行。”Guntaka博士說:“我很高興加入Adiso，這是一家充滿活力的公司，在炎症疾病的局部作用多模式療法方麵取得了重大進展，這些療法比目前可用的更有效，而且可能遠低於免疫抑製。”“該公司的使命是真正傾聽患者的心聲，以改善他們及其家庭成員的生活，這與作為醫療保健提供者的我產生了共鳴。”Guntaka博士在開發炎症性疾病治療方麵擁有豐富的經驗。在加入Adiso和Mirum之前，他曾擔任Abbvie消化病學(美國醫療事務)副醫療總監，在那裏他為核心醫療事務活動提供戰略和運營投入。 Before that, Dr. Guntaka was Sr. Manager, Clinical Development (LS&O) at Baxter Healthcare where he collaborated with medical affairs, pharmacovigilance, regulatory affairs and commercial organizations to drive clinical development programs. In addition, Dr. Guntaka is a published author of numerous papers and presentations. He received his M.D. from Sri Ramachandra Medical College & Research Institute. About Adiso: Adiso is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients and their families by creating new medicines to treat inflammatory diseases. This dedication is epitomized by our lead clinical candidates, ADS051, an oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis; ADS032, a dual NLRP3/NLRP1 inflammasome inhibitor initially being developed for inflammatory diseases of the lung; and ADS024, an oral single strain live biotherapeutic product (SS-LBP) for the treatment of ulcerative colitis and prevention of C. difficile recurrence. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University College Cork, Ireland, the APC Microbiome Institute, the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia and the University of Edinburgh Centre for Inflammation Research. For more information, please visit www.adisotx.com or our LinkedIn page. Contacts